

Edgar Filing: CELSION CORP - Form 8-K

CELSION CORP  
Form 8-K  
April 03, 2002

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): March 28, 2002  
-----

Celsion Corporation

-----  
(Exact Name of Registrant as Specified in Charter)

Delaware	000-14242	52-1256615
-----	-----	-----
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

10220-I Old Columbia Road, Columbia, Maryland	21046-1705
-----	-----
(Address of principal executive office)	(Zip Code)

Registrant's telephone number, including area code: (410) 290-5390  
-----

-----  
(Former Name or Former Address, if Changed Since Last Report)

ITEM 5. OTHER EVENTS

On March 28, 2002, the Company issued a press release reporting, among other things, results from the multi-site Phase II pivotal trial of its Microfocus BPH 800 Microwave Urethroplasty(TM) system used for the treatment of Benign Prostatic Hyperplasia, is a non-cancerous urological disease that affects many older men. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K.

Edgar Filing: CELSION CORP - Form 8-K

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CELSION CORPORATION

Date: April 2, 2002

By: /s/ Anthony P. Deasey

-----  
Anthony P. Deasey  
Executive Vice President - Finance  
and Administration and  
Chief Financial Officer

-3-

EXHIBIT INDEX

Exhibit -----	Description -----
99.1	Press Release dated March 28, 2002.